Drugs / AGT-182
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02262338 | Apr 2015 → Mar 2017 | mucopolysaccharidosis type 2 | ArmaGen, Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGT-182 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02262338 ↗ |
| Modality | Protein / enzyme biologic | “AGT-182 is a fusion protein containing idursulfase” NCT02262338 ↗ |
| Route | Intravenous | “administered intravenously” NCT02262338 ↗ |